Abstract
Phthalimide derivate compounds was reported as a new class of nonnucleoside reverse tranckriptase inhibitors. The aim of this research is to determine the prediction of absorption, distribution, metabolism, and excretion (ADME) as well as the toxicity test of phthalimide-derived compounds which have the best potential as HIV-1 reverse transcriptase enzyme inhibitors. This study used an in silico approach to predict oral bioavailability and toxicity. The prediction of the ADME in this study using SwissADME which is run online where thirty-three phthalimide derivate compounds have molecular weight, hydrogen donor and acceptor bond, and log P that meet the criteria of Lipinski Rules. Prediction of toxicity in this study using in silico method with Toxtree v1.60 and it is known that phthalimide derivate compounds are not carcinogenic and mutagenic.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Proceedings of the International Conference on Nursing and Health Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.